insights_auto
Outlook: 64.7% bullish·11.8% bearish
Go to analysischevron_right
ARGX:NASDAQ
argenx SE - ADR
$928.44
arrow_downward
-0.22%(-2.08) 1D
$784.78
arrow_downward
-15.47% (-143.66)todayPre-market
Closed: Oct 7, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARGX...
Open
$932.08
High
$942.68
Low
$921.72
Mkt. cap
58.78B
Avg. vol.
259.69K
Volume
70.48K
P/E ratio
35.27
52-wk high
$1,072.75
52-wk low
$661.85
EPS
$26.32
Beta
0.45
Shares outstanding
62.89M
No. of employees
2K
Open
$932.08
High
$942.68
Low
$921.72
Mkt. cap
58.78B
Avg. vol.
259.69K
Volume
70.48K
P/E ratio
35.27
52-wk high
$1,072.75
52-wk low
$661.85
EPS
$26.32
Beta
0.45
Shares outstanding
62.89M
No. of employees
2K
News stories
From web sources and news partners
TradingView
·
35 minutes ago
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble
Seeking Alpha
·
58 minutes ago
Argenx stock falls on late-stage trial setback (ARGX:NASDAQ)
News Corp
·
1 hour ago
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
WSJ
·
1 hour ago
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE - ADR